Abstract:Inappropriate cell proliferation during oncogenesis is often attributed to dysregulation of components of the cell cycle machinery, which is strictly controlled by the activity of cyclins, cyclin-dependent kinases (CDKs) and cyclin-dependent kinases inhibitors (CKI). In our previous study, we have reported that the oncogenic fusion protein PML/RARa directly targets and represses the expression of CDKN2D, one of the CKI member, in acute promyelocytic leukemia (APL). Since different members of CKIs can mediate separate pathways to negatively regulate CDKs so as to control the cell cycle progression, thus implicating that multiple components of CKIs might be affected during the malignant transformation. However, the transcription regulation of the overall machinery of CKIs in APL remains unclear. Here, we report that PML/RARa coordinately represses multiple members of CKIs by directly binding to their regulatory regions. To identify potential CKIs that were dys-regulated in APL cells, we first studied the chromatin status of all the CKIs in APL by chromatin immunoprecipitation combined with next generation sequencing (ChIP-seq) using antibodies against histone modification markers (H3K4me3, H3K4me1 and H3K27me3). We found that the regulatory regions of CDKN2C, CDKN2D and CDKN1A were accessible in APL, suggesting that these CKIs were dynamically regulated in APL. We then performed ChIP-seq using antibody against PML/RARa and found that these three CKIs were occupied with PML/RARa binding, indicating that PML/RARa coordinately regulated CKIs in APL. To further study the role of PML/RARa in transcription regulation of CKIs, we used luciferase reporter assays to detect the effect of PML/RARα on CKIs transcription regulation and found that PML/RARα directly inhibited the promoter activity of CDKN2C and CDKN2D. Furthermore, we demonstrated that ATRA treatment increased the expression of CDKN2C, CDKN2D and CDKN1A through releasing the PML/RARα binding on chromatin in NB4 cells. Ectopic expression of these three CKIs could induce both cell cycle arrest and differentiation. Finally, the finding on the transcriptional regulation of CDKN1A, CDKN2C and CDKN2D in NB4 cells was validated in primary APL patient samples. Collectively, this study emphasizes that PML/RARa represses the CKI machinery and leads to cell cycle progression and differentiation block of APL. The coordinated regulation of multi-factors involved in the same pathway may shed new lights on the study of pathogenesis and target therapy of APL.Disclosures No relevant conflicts of interest to declare.

Effect of promyelocytic leukemia-retinoic acid receptor fusion protein on transcriptional regulation of LMO2

PML‐RARα Interferes with Erythropoiesis by Repressing LMO2 in Acute Promyelocytic Leukaemia

A Distinct Epigenetic Signature at Targets of a Leukemia Protein

The transcriptional downregulation of RIAM gene mediated by PML-RARα fusion protein

A PML/RARα Direct Target Atlas Redefines Transcriptional Deregulation in Acute Promyelocytic Leukemia

Transcriptional Repression of CDKN2D by PML/RARα Contributes to the Altered Proliferation and Differentiation Block of Acute Promyelocytic Leukemia Cells

[Transcriptional Regulation of BHLHB2 Induced by PML-RARα].

Chromatin Topology Reorganization and Transcription Repression by PML/RARα in Acute Promyeloid Leukemia

Coordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia

The impact of differential binding of wild-type RARα, PML-, PLZF- and NPM-RARα fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia

Repression of CDKN2C Caused by PML/RARα Binding Promotes the Proliferation and Differentiation Block in Acute Promyelocytic Leukemia

[Effects of PML-RARalpha on Camp-Induced AML Cell Differentiation].

Aberrant Chromatin Remodeling by Retinoic Acid Receptor Alpha Fusion Proteins Assessed at the Single-Cell Level

[Abnormal Expression of Transcription Factors LYL1 and LMO2 and Interaction Between Them in Myeloid Leukemia].

LMO2 Promotes the Development of AML Through Interaction with Transcription Co-Regulator LDB1

[Effects of interferon regulatory factor 9 on the biological phenotypes in PML-RARα-induced promyelocytic leukemia]

Coordinated Repression Of Cyclin-Dependent Kinase Inhibitors By Pml/Rara In Acute Promyelocytic Leukemia

Nls-Rar Alpha Promotes Proliferation And Inhibits Differentiation In Hl-60 Cells

Involvement of PML-I in Reformation of PML Nuclear Bodies in Acute Promyelocytic Leukemia Cells by Leptomycin B

The PML-RARα Fusion Protein and Targeted Therapy for Acute Promyelocytic Leukemia

Comparative Proteomic Analysis of All-Trans-retinoic Acid Treatment Reveals Systematic Posttranscriptional Control Mechanisms in Acute Promyelocytic Leukemia